Pharmaceutical composition and biomaterial comprising fusion peptide in which bone tissue-selective peptide bound to parathyroid hormone (pth) or fragment thereof

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide bound to parathyroid hormone (PTH) or a fragment thereof. More particularly, the present invention relates to a pharmaceutical composition and biomaterial for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide represented by an amino acid sequence of SEQ ID NO. 3 bound to parathyroid hormone (PTH) or a fragment thereof represented by an amino acid sequence of SEQ ID NO. 4 or 5. The fusion peptide can improve effects of PTH by selectively binding to bone tissue and can reduce administration frequency by increasing the half-life. The fusion peptide can be used as a subcutaneous or intravenous injection-type pharmaceutical composition for treating osteoporosis and fracture, and can be used in combination with a medical device for tissue recovery to increase formation of bone tissue. In addition, when the fusion peptide is bound to the surface of dental and orthopedic medical devices, transplantation stability of the medical device can be improved through improved osseointegration between the medical device and new bone.